Details for Patent: 8,669,380

Title:	Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Abstract:	Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001##
Inventor(s):	Mascitti; Vincent (Groton, CT)
Assignee:	Pfizer Inc. (New York, NY)
Filing Date:	Oct 21, 2010
Application Number:	13/498,702
Claims:	1. A compound of Formula (A) or Formula (B) ##STR00048## wherein R is --OH; R.sup.1 is --OH; and R.sup.2 is --OH and pharmaceutically acceptable salts thereof. 2. A compound of Formula (A) or Formula (B) ##STR00049## wherein R is --OH; R.sup.1 is --OH; and R.sup.2 is --O--CH.sub.2CH.sub.2OH and pharmaceutically acceptable salts thereof. 3. A compound selected from the group consisting of: Acetic acid (1R,2S,3S,4R,5S)-3,4-diacetoxy-1-acetoxymethyl-5-[4-chloro-3-(4-ethoxy-be- nzyl)-phenyl]-6,8-dioxa-bicyclo[3.2.1]oct-2-yl ester; Acetic acid (1R,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,3,4-trihydoxy-- 6,8-dioxa-bicyclo[3.2.1]oct-1-ylmethyl ester; Carbonic acid (1R,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-2,3,4-trihydoxy-- 6,8-dioxa-bicyclo[3.2.1]oct-1-ylmethyl ester ethyl ester; [D.sub.5]-(1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydr- oxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; Acetic acid 2-{4-[2-chloro-5-((1S,2S,3S,4R,5S)-2,3,4-trihydroxy-1-hydroxymethyl-6,8-d- ioxa-bicyclo[3.2.1]oct-5-yl)-benzyl]-phenoxy}-ethyl ester; (1S,2S,3S,4R,5S)-5-{4-Chloro-3-[4-(2-hydroxy-ethoxy)-benzyl]-phenyl}-1-hy- droxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; and (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-fluoromethyl-6- ,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; or a pharmaceutically acceptable salt thereof. 4. A compound (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-hydroxy-benzyl)-phenyl]-1-hydroxymethyl- -6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol. 5. A compound selected from the group consisting of: (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxy-phenyl)-hydroxy-methyl]-phenyl}- -1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; (1S,2S,3S,4R,5S)-5-{4-Chloro-3-[(R)-(4-ethoxy-phenyl)-hydroxy-methyl]-phe- nyl}-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol; and (1S,2S,3S,4R,5S)-5-{4-Chloro-3-[(S)-(4-ethoxy-phenyl)-hydroxy-methyl]-phe- nyl}-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol. 6. A pharmaceutical composition comprising: (i) a compound of claim 1, 2, 3, 4, or 5 or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient, diluent, or carrier. 7. The composition of claim 6 wherein said compound or said therapeutically acceptable salt thereof is present in a therapeutically effective amount. 8. The composition of claim 6 further comprising at least one additional pharmaceutical agent selected from the group consisting of an anti-obesity agent and an anti-diabetic agent. 9. The composition of claim 8 wherein said anti-obesity agent is selected from the group consisting of rimonabant, taranabant, surinabant, otenabant, SLV319 (CAS No. 464213-10-3), AVE1625 (CAS No. 358970-97-5)), dirlotapide, mitratapide, implitapide, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorcaserin, cetilistat, PYY.sub.3-36, naltrexone, oleoyl-estrone, obinepitide, pramlintide, tesofensine, leptin, liraglutide, bromocriptine, orlistat, exenatide, AOD-9604 (CAS No. 221231-10-3) and sibutramine. 10. The composition of claim 8 wherein said anti-diabetic agent is selected from the group consisting of metformin, acetohexamide, chlorpropamide, diabinese, glibenclamide, glipizide, glyburide, glimepiride, gliclazide, glipentide, gliquidone, glisolamide, tolazamide, tolbutamide, tendamistat, trestatin, acarbose, adiposine, camiglibose, emiglitate, miglitol, voglibose, pradimicin-Q, salbostatin, balaglitazone, ciglitazone, darglitazone, englitazone, isaglitazone, pioglitazone, rosiglitazone, troglitazone, exendin-3, exendin-4, liraglutide, trodusquemine, reservatrol, hyrtiosal extract, sitagliptin, vildagliptin, alogliptin and saxagliptin.